Drugs / Famitinib
Trials 70 · started per year
today
1
4
3
1
2
1
1
5
6
17
8
5
7
4
5
20092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT05473468 | Aug → Nov 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05147727 | Mar → May 2022 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05103826 | Oct 2021 → Jun 2023 | estrogen-receptor positive breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT05046808 | Sep → Oct 2021 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05041920 | Sep → Oct 2021 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04494659 | Jul → Aug 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02364362 | Jan 2015 → Dec 2018 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01462474 | Oct 2011 → Aug 2015 | nasopharyngeal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01762280 | Jun 2009 → Apr 2012 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07662681 | Jul 2026 → Jul 2028 expected | head and neck cancer | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06332950 | Apr 2024 → Apr 2027 expected | small cell lung carcinoma | Baohui Han | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05176080 | Dec 2021 → Jul 2024 | breast cancer | Henan Cancer Hospital | Terminated | No outcome recorded |
| Phase 1/2 | NCT05020925 | Sep 2021 → May 2022 | nasopharyngeal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04679038 | Mar 2021 → Dec 2022 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04044378 | Aug 2019 → Sep 2021 | pediatric osteosarcoma | Peking University People's Hospital | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03805399 | Oct 2018 → Dec 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 243 trials | ||||||
| Phase 2 | NCT07627620 | Jun 2026 → Sep 2027 expected | cervical cancer | Hunan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07517653 | Apr 2026 → Nov 2028 expected | melanoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07382713 | Feb 2026 → Dec 2030 expected | ovarian cancer | Jinhua Zhou | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07355010 | Dec 2025 → Dec 2028 expected | ovarian cancer | Qinglei Gao | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07143292 | Nov 2025 → Dec 2026 expected | cervical cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07147088 | Sep 2025 → Sep 2027 expected | intrahepatic cholangiocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06649331 | Oct 2024 → Sep 2026 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06516289 | Sep 2024 → Jun 2026 overdue | Her2-receptor negative breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07309185 | Jul 2024 → Jul 2027 expected | gastric neoplasm | Shandong Tumor Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06336954 | Mar → Jul 2024 overdue | non-small cell lung carcinoma | Second Affiliated Hospital of Xi'an Jiaotong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06306560 | Mar 2024 → Mar 2027 expected | small cell lung carcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06332300 | Feb 2024 → Feb 2025 | non-small cell lung carcinoma | Jiangsu Province Nanjing Brain Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT06146985 | Dec 2023 → Nov 2024 | thyroid cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05749588 | Mar 2023 → Dec 2027 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05670925 | Mar → Sep 2023 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05594095 | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05214976 | Aug 2022 → Jan 2023 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05208177 | Apr 2022 → Aug 2023 | neoplastic disease or syndrome | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT05051865 | Oct 2021 → Aug 2024 | melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05005468 | Sep 2021 → Aug 2023 | non-small cell lung carcinoma | Shanghai Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04888429 | Jul 2021 → Dec 2024 overdue | lung sarcomatoid carcinoma | Qian Chu | Recruiting | No outcome recorded |
| Phase 2 | NCT04884009 | May 2021 → Dec 2022 | lung cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04733417 | May 2021 → Aug 2022 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04814485 | Apr 2021 → Jul 2023 | malignant pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04680988 | Apr 2021 → Jul 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04866381 | Apr 2021 → Apr 2023 | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04699968 | Jan → Nov 2021 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04479904 | Aug 2020 → Dec 2021 | intrahepatic cholangiocarcinoma | Jiangsu HengRui Medicine Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04395989 | Jul 2020 → May 2023 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04346381 | Jun 2020 → Jun 2022 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04355858 | May 2020 → May 2023 | breast cancer, metastatic malignant neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04521348 | Dec 2019 → Dec 2024 | thyroid cancer | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT04129996 | Oct 2019 → Sep 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03904823 | Apr 2019 → Dec 2022 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03827837 | Jan 2019 → Dec 2022 | cervical cancer, endometrial cancer, ovarian carcinoma, renal cell carcinoma +1 | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02356991 | Dec 2014 → Jun 2020 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Suspended | No outcome recorded |
| Phase 2 | NCT01653574 | May 2012 → Nov 2013 | breast neoplasm | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT01762293 | Apr 2012 → Sep 2014 | colorectal cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02336724 | Mar 2012 → Dec 2018 | gastrointestinal stromal tumor | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01994213 | Oct 2011 → Nov 2015 | digestive system neuroendocrine neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT01392235 | Jul 2011 → Apr 2015 | nasopharyngeal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01829841 | May 2011 → Apr 2013 | renal cell carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT07382687 | Feb 2026 → Dec 2028 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06913777 | Apr 2025 → Oct 2026 expected | — | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05999149 | Aug 2023 → Aug 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05760378 | Mar 2023 → Jan 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05042375 | Sep 2022 → Dec 2023 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05106335 | Jan → May 2022 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04906993 | Jul 2021 → Jun 2025 overdue | cervical cancer | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04619433 | Feb 2021 → Aug 2025 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04409223 | Sep 2020 → Mar 2022 | gastrointestinal stromal tumor | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT02766140 | Jun → Nov 2016 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT02390947 | Jan 2015 → Feb 2019 | metastasis from malignant tumor of colon | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 73 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Famitinib | “Adibelimab (1200mg, IV, every 3 weeks) combined with Famitinib (20mg, daily, orally) and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks)” NCT06336954 ↗64“famitinib plus anti-PD-1 antibody could advance TLS in thyroid cancer.” PMID 38478516 ↗ Mar 2024 “and famitinib 20mg qd continuously” NCT03805399 ↗ |
| Known as | C1: PD-1 with nab-paclitaxel and famitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04395989 ↗ |
| Known as | Famitinib Malate | “Famitinib Malate Capsules 10mg single dose” NCT05046808 ↗3“famitinib malate, 25 mg on study day 1” NCT05041920 ↗ “Famitinib malate capsules, 20 mg” NCT05042375 ↗ “Famitinib malate capsules, qd.” NCT05208177 ↗ |
| Known as | SHR1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02766140 ↗ |
| Action | Inhibit | “tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3” NCT01392235 ↗1“Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL1278146 ↗ |
| Modality | Small molecule | “Famitinib is a small-molecule multikinase inhibitor” PMID 29273089 ↗ Dec 2017 |
| Route | Oral | “25 mg qd p.o.” NCT01392235 ↗ |
| Target | FLT4 | “Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL1278146 ↗ |
| Target | KDR | “Famitinib is an inhibitor of multiple tyrosine kinases mainly targeting VEGFR-2.” PMID 24939214 ↗ Jun 2014 |